Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Sungkyunkwan University · Samsung Medical Center · +24 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,171
total citations
- FWCI
- 111.05
- Percentile
- 100%
- References
- 35
Citations per year
Authors
23- KPKeunchil ParkCorresponding
Sungkyunkwan University, Samsung Medical Center
- ETEng-Huat Tan
National Cancer Centre Singapore
- KJKenneth J. O’Byrne
Princess Alexandra Hospital, Queensland University of Technology
- LZLi Zhang
Sun Yat-sen University Cancer Center, Sun Yat-sen University
- MBMichael Boyer
Chris O’Brien Lifehouse
Topics & keywords
Topics
Keywords
- Afatinib
- Gefitinib
- Medicine
- Internal medicine
- Lung cancer
- Oncology
- Population
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.